Level of RUNX1 activity is critical for leukemic predisposition but not for thrombocytopenia

Blood

Volumn 125, Issue 6, 2015, Pages 930-940

  Antony Debré, Iléana ^a,b,c   Manchev, Vladimir T ^a,c   Balayn, Nathalie ^a,d   Bluteau, Dominique ^a,d,e   Tomowiak, Cécile ^a,d,f   Legrand, Céline ^a,d   Langlois, Thierry ^a,d   Bawa, Olivia ^a   Tosca, Lucie ^g   Tachdjian, Gérard ^g   Leheup, Bruno ^h,i   Debili, Najet ^a,d   Plo, Isabelle ^a,d   Mills, Jason A ^j   French, Deborah L ^j   Weiss, Mitchell J ^j   Solary, Eric ^a,d   Favier, Remi ^a,k   Vainchenker, William ^a,d   Raslova, Hana ^a,d  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b HENRI MONDOR HOSPITAL   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d UNIVERSITÉ PARIS SACLAY   (France)

^e PSL RESEARCH UNIVERSITY   (France)

^f POITIERS UNIVERSITY HOSPITAL   (France)

^g INSERM   (France)

^h UNIVERSITY HOSPITAL OF NANCY   (France)

ⁱ UNIVERSITÉ DE LORRAINE   (France)

^j CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^k ARMAND TROUSSEAU HOSPITAL   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

TRANSCRIPTION FACTOR RUNX1; RUNX1 PROTEIN, HUMAN;

ARTICLE; CANCER SUSCEPTIBILITY; CELL COUNT; CELL DIFFERENTIATION; CONTROLLED STUDY; DOMINANT INHERITANCE; DOWN REGULATION; EMBRYO; EMBRYONIC STEM CELL; ERYTHROPOIESIS; GENE; GENE DELETION; GENE SILENCING; GENOMIC INSTABILITY; GERMLINE MUTATION; HAPLOINSUFFICIENCY; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; LEUKEMIA; MEGAKARYOPOIESIS; MISSENSE MUTATION; MOLECULAR CLONING; MONOCYTE; PEDIGREE; PHENOTYPE; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RUNX1 GENE; THROMBOCYTOPENIA; CELL CULTURE; CELL LINE; CYTOLOGY; GENETIC PREDISPOSITION; GENETICS; HEMATOPOIESIS; METABOLISM; MOLECULAR GENETICS; MUTATION; PATHOLOGY;

CELL LINE; CELLS, CULTURED; CORE BINDING FACTOR ALPHA 2 SUBUNIT; GENE DELETION; GENETIC PREDISPOSITION TO DISEASE; GENOMIC INSTABILITY; HEMATOPOIESIS; HUMANS; INDUCED PLURIPOTENT STEM CELLS; LEUKEMIA; MOLECULAR SEQUENCE DATA; MUTATION; MUTATION, MISSENSE; THROMBOCYTOPENIA;

EID: 84922387310     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-06-585513     Document Type: Article

References (47)

1. Song WJ, Sullivan MG, Legare RD, et al. Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. Nat Genet. 1999; 23(2): 166-175.
2. Béri-Dexheimer M, Latger-Cannard V, Philippe C, et al. Clinical phenotype of germline RUNX1 haploinsufficiency: from point mutations to large genomic deletions. Eur J Hum Genet. 2008; 16(8): 1014-1018.
3. Michaud J, Wu F, Osato M, et al. In vitro analyses of known and novel RUNX1/AML1 mutations in dominant familial platelet disorder with predisposition to acute myelogenous leukemia: implications for mechanisms of pathogenesis. Blood. 2002; 99(4): 1364-1372.
4. Bluteau D, Gilles L, Hilpert M, et al. Down-regulation of the RUNX1-target gene NR4A3 contributes to hematopoiesis deregulation in familial platelet disorder/acute myelogenous leukemia. Blood. 2011; 118(24): 6310-6320.
5. Preudhomme C, Renneville A, Bourdon V, et al. High frequency of RUNX1 biallelic alteration in acute myeloid leukemia secondary to familial platelet disorder. Blood. 2009; 113(22): 5583-5587.
6. Grimwade D, Hills RK, Moorman AV, et al.; National Cancer Research Institute Adult Leukaemia Working Group. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010; 116(3): 354-365.
7. Gaidzik VI, Bullinger L, Schlenk RF, et al. RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group. J Clin Oncol. 2011; 29(10): 1364-1372.
8. Tang JL, Hou HA, Chen CY, et al. AML1/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: prognostic implication and interaction with other gene alterations. Blood. 2009; 114(26): 5352-5361.
9. Schnittger S, Dicker F, Kern W, et al. RUNX1 mutations are frequent in de novo AML with noncomplex karyotype and confer an unfavorable prognosis. Blood. 2011; 117(8): 2348-2357.
10. Itzykson R, Kosmider O, Renneville A, et al. Prognostic score including gene mutations in chronic myelomonocytic leukemia. J Clin Oncol. 2013; 31(19): 2428-2436.
11. Kohlmann A, Grossmann V, Klein HU, et al. Nextgeneration sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1. J Clin Oncol. 2010; 28(24): 3858-3865.
12. Bejar R, Stevenson K, Abdel-Wahab O, et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med. 2011; 364(26): 2496-2506.
13. Flach J, Dicker F, Schnittger S, et al. An accumulation of cytogenetic and molecular genetic events characterizes the progression from MDS to secondary AML: an analysis of 38 paired samples analyzed by cytogenetics, molecular mutation analysis and SNP microarray profiling. Leukemia. 2011; 25(4): 713-718.
14. Okuda T, van Deursen J, Hiebert SW, Grosveld G, Downing JR. AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. Cell. 1996; 84(2): 321-330.
15. Growney JD, Shigematsu H, Li Z, et al. Loss of Runx1 perturbs adult hematopoiesis and is associated with a myeloproliferative phenotype. Blood. 2005; 106(2): 494-504.
16. Ichikawa M, Asai T, Saito T, et al. AML-1 is required for megakaryocytic maturation and lymphocytic differentiation, but not for maintenance of hematopoietic stem cells in adult hematopoiesis. Nat Med. 2004; 10(3): 299-304.
17. Yokomizo T, Hasegawa K, Ishitobi H, et al. Runx1 is involved in primitive erythropoiesis in the mouse. Blood. 2008; 111(8): 4075-4080.
18. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006; 126(4): 663-676.
19. Satoh Y, Matsumura I, Tanaka H, et al. C-terminal mutation of RUNX1 attenuates the DNA-damage repair response in hematopoietic stem cells. Leukemia. 2012; 26(2): 303-311.
20. Klimchenko O, Mori M, Distefano A, et al. A common bipotent progenitor generates the erythroid and megakaryocyte lineages in embryonic stem cell-derived primitive hematopoiesis. Blood. 2009; 114(8): 1506-1517.
21. Amit M, Carpenter MK, Inokuma MS, et al. Clonally derived human embryonic stem cell lines maintain pluripotency and proliferative potential for prolonged periods of culture. Dev Biol. 2000; 227(2): 271-278.
22. Mills JA, Wang K, Paluru P, et al. Clonal genetic and hematopoietic heterogeneity among human-induced pluripotent stem cell lines. Blood. 2013; 122(12): 2047-2051.
23. Kim K, Doi A, Wen B, et al. Epigenetic memory in induced pluripotent stem cells. Nature. 2010; 467(7313): 285-290.
24. Polo JM, Liu S, Figueroa ME, et al. Cell type of origin influences the molecular and functional properties of mouse induced pluripotent stem cells. Nat Biotechnol. 2010; 28(8): 848-855.
25. Bluteau D, Glembotsky AC, Raimbault A, et al. Dysmegakaryopoiesis of FPD/AML pedigrees with constitutional RUNX1 mutations is linked to myosin II deregulated expression. Blood. 2012; 120(13): 2708-2718.
26. Lordier L, Bluteau D, Jalil A, et al. RUNX1-induced silencing of non-muscle myosin heavy chain IIB contributes to megakaryocyte polyploidization. Nat Commun. 2012; 3: 717.
27. Tiyaboonchai A, Mac H, Shamsedeen R, et al. Utilization of the AAVS1 safe harbor locus for hematopoietic specific transgene expression and gene knockdown in human ES cells. Stem Cell Res (Amst). 2014; 12(3): 630-637.
28. Chen MJ, Yokomizo T, Zeigler BM, Dzierzak E, Speck NA. Runx1 is required for the endothelial to haematopoietic cell transition but not thereafter. Nature. 2009; 457(7231): 887-891.
29. Liakhovitskaia A, Gribi R, Stamateris E, et al. Restoration of Runx1 expression in the Tie2 cell compartment rescues definitive hematopoietic stem cells and extends life of Runx1 knockout animals until birth. Stem Cells. 2009; 27(7): 1616-1624.
30. Sakurai M, Kunimoto H, Watanabe N, et al. Impaired hematopoietic differentiation of RUNX1-mutated induced pluripotent stem cells derived from FPD/AML patients. Leukemia. 2014; 28(12): 2344-2354.
31. Chang KH, Nelson AM, Fields PA, et al. Diverse hematopoietic potentials of five human embryonic stem cell lines. Exp Cell Res. 2008; 314(16): 2930-2940.
32. Maclean GA, Menne TF, Guo G, et al. Altered hematopoiesis in trisomy 21 as revealed through in vitro differentiation of isogenic human pluripotent cells. Proc Natl Acad Sci USA. 2012; 109(43): 17567-17572.
33. Vodyanik MA, Thomson JA, Slukvin II. Leukosialin (CD43) defines hematopoietic progenitors in human embryonic stem cell differentiation cultures. Blood. 2006; 108(6): 2095-2105.
34. Rafii S, Kloss CC, Butler JM, et al. Human ESC-derived hemogenic endothelial cells undergo distinct waves of endothelial to hematopoietic transition. Blood. 2013; 121(5): 770-780.
35. Connelly JP, Kwon EM, Gao Y, et al. Targeted correction of RUNX1 mutation in FPD patient-specific induced pluripotent stem cells rescues megakaryopoietic defects [published online ahead of print August 11, 2014]. Blood. 2014.
36. Ramirez-Herrick AM, Mullican SE, Sheehan AM, Conneely OM. Reduced NR4A gene dosage leads to mixed myelodysplastic/myeloproliferative neoplasms in mice. Blood. 2011; 117(9): 2681-2690.
37. Boudreaux SP, Ramirez-Herrick AM, Duren RP, Conneely OM. Genome-wide profiling reveals transcriptional repression of MYC as a core component of NR4A tumor suppression in acute myeloid leukemia. Oncogenesis. 2012; 1:e19.
38. Mullican SE, Zhang S, Konopleva M, et al. Abrogation of nuclear receptors Nr4a3 and Nr4a1 leads to development of acute myeloid leukemia. Nat Med. 2007; 13(6): 730-735.
39. Satpathy AT, Briseño CG, Cai X, et al. Runx1 and Cbfb regulate the development of Flt31 dendritic cell progenitors and restrict myeloproliferative disorder. Blood. 2014; 123(19): 2968-2977.
40. Goyama S, Schibler J, Cunningham L, et al. Transcription factor RUNX1 promotes survival of acute myeloid leukemia cells. J Clin Invest. 2013; 123(9): 3876-3888.
41. Rosenbauer F, Wagner K, Kutok JL, et al. Acute myeloid leukemia induced by graded reduction of a lineage-specific transcription factor, PU.1. Nat Genet. 2004; 36(6): 624-630.
42. Scott EW, Fisher RC, Olson MC, Kehrli EW, Simon MC, Singh H. PU.1 functions in a cell-autonomous manner to control the differentiation of multipotential lymphoid-myeloid progenitors. Immunity. 1997; 6(4): 437-447.
43. Olson MC, Scott EW, Hack AA, et al. PU. 1 is not essential for early myeloid gene expression but is required for terminal myeloid differentiation. Immunity. 1995; 3(6): 703-714.
44. Gore A, Li Z, Fung HL, et al. Somatic coding mutations in human induced pluripotent stem cells. Nature. 2011; 471(7336): 63-67.
45. Wu D, Ozaki T, Yoshihara Y, Kubo N, Nakagawara A. Runt-related transcription factor 1 (RUNX1) stimulates tumor suppressor p53 protein in response to DNA damage through complex formation and acetylation. J Biol Chem. 2013; 288(2): 1353-1364.
46. Michaud J, Simpson KM, Escher R, et al. Integrative analysis of RUNX1 downstream pathways and target genes. BMC Genomics. 2008; 9: 363.
47. Harada H, Harada Y, Tanaka H, Kimura A, Inaba T. Implications of somatic mutations in the AML1 gene in radiation-associated and therapy-related myelodysplastic syndrome/acute myeloid leukemia. Blood. 2003; 101(2): 673-680.